Jun. 30 at 9:18 PM
$KYTX FYI...KYTX is going to plant the flag first on use of CAR-T for Autoimmune with SPS first. This company has more cash runway than CABA as well which is important in this phase. Goal to buy a little more on red days.
Cabaletta CABA is Kyverna's closest competitor in using Car-t therapy in autoimmune disease
CABA is widely considered Kyverna's closest direct competitor. Both are specialized, clinical-stage biotechnology companies focused primarily on developing CD19-directed CAR-T cell therapies to deplete pathogenic B-cells in various autoimmune diseases.
While Kyverna is positioned as a "depth-first" leader (first-in-field BLA for SPS), Cabaletta Bio is its closest peer in developing a broad pipeline across a wide range of autoimmune indications, such as systemic lupus erythematosus (SLE) and myositis.
Other companies racing to bring CAR-T to the autoimmune space include Cartesian Therapeutics and Novartis. GLTY
